Profit before interest, taxes and amortization: tevogen.com (TVGN)
Tevogen Bio Holdings (TVGN) has optimized costs by outsourcing drug production to external CDMO partners. Operating cash flow before interest and taxes confirms a lack of profit, where 0.00 is recorded as the baseline value. The company is developing affordable T-cell cancer therapy via its proprietary platform. However, the absence of revenue and reliance on secondary offerings during early-stage clinical trials create high investment risks.
Tevogen Bio Holdings, Inc. - analytical breakdowns and key metrics (TVGN)
- stock price and consensus target price:
- company stock exchange capitalization indicators:
- book capitalization data:
- business debt structure and liquidity details:
Debt to Equity Ratio Tevogen Bio Holdings|TVGN - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Tevogen Bio Holdings, Inc.|TVGN - Company Aggregate Debts|Debt to Book Capitalization Ratio Tevogen Bio Holdings|TVGN - Company Long-Term Debts|Short-Term Debt Volume Tevogen Bio|Immediate Liquidity tevogen.com
- net income and valuation ratios data:
TVGN - Net Income|Expected Net Income Tevogen Bio Holdings|TVGN - P/E Multiple|Future Price to Earnings Multiple Tevogen Bio Holdings Inc.|TVGN - Price/Earnings to Growth Ratio|Company Value to EBITDA Tevogen Bio Holdings Inc.|TVGN - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Tevogen Bio|TVGN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months tevogen.com|TVGN - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Tevogen Bio Holdings
- sales revenue and business income indicators:
Summary company analytics:Tevogen Bio Holdings (TVGN)
For investors, evaluating Tevogen Bio Holdings (TVGN) requires an analysis of the company's ability to generate cash flow during a period of intensive R&D for T-cell therapies. The projected EBITDA reflects the actual volume of operating cash inflow before depreciation and interest, determining whether internal resources are sufficient to scale personalized medicine without a critical dependence on costly external financing or the risk of capital freezes.
Who Tevogen Bio Holdings competes with
Biogen Inc. (BIIB) - Profit before interest, taxes and amortization|NBIX - Profit before payment of interest, taxes and amortization|RGC (Regencell Bioscience Holdings Limited) - Operating profit before amortization|Axsome Corp (AXSM) - Profit before payment of interest, taxes and amortization|ACAD - Operating income before deduction of amortization|Operating profit before deduction of amortization XENE|VKTX - Operating profit before depreciation charges|Operating profit before deduction of amortization SUPN (supernus.com)|Operating income before deduction of amortization Catalyst Pharmaceuticals Inc|Denali Therapeutics Inc. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization HRMY|BHVN: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization AMLX (Amylyx Pharmaceuticals)|Trevi Therapeutics, Inc. (TRVI) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Praxis Precision Medicines, Inc. (PRAX)|AVXL (anavex.com) - Operating profit EBITDA|Operating profit before amortization CBLL (CeriBell Corp)|Profit before payment of interest, taxes and amortization Prothena Biosciences (PRTA)|Operating income before deduction of amortization Alector|Operating profit EBITDA ANNX (annexonbio.com)|Income before deduction of interest, taxes and amortization OMER|NGNE: Operating profit before deduction of amortization|ACIU (AC Immune Corp) - Operating profit before amortization|VYGR: Operating profit EBITDA|Profit before interest, taxes and amortization Neumora Therapeutics, Inc. (NMRA)|SCLX (Scilex Holding) - Operating profit EBITDA|Operating profit EBITDA Alpha Cognition|Operating profit EBITDA CGTX|IKT - Profit before interest, taxes and amortization|Operating profit EBITDA SAVA (cassavasciences.com)|Income before deduction of interest, taxes and amortization ASRT|Coya Therapeutics Inc - Operating profit EBITDA|Operating income before deduction of amortization vistagen.com VTGN|Ovid Therapeutics Inc. (OVID) - Profit before payment of interest, taxes and amortization|Acumen Pharmaceuticals, Inc (ABOS) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization CervoMed Inc.|Alterity Therapeutics (ATHE) - Operating income before deduction of amortization|Operating profit EBITDA CLNN|PEPG - Profit before interest, taxes and amortization|Operating profit EBITDA JUNS (Jupiter Neurosciences, Inc.)|RLMD - Operating profit before deduction of amortization|ANVS - Profit before payment of interest, taxes and amortization|Operating profit before depreciation charges Grace Therapeutics (GRCE)|AIFF: Operating profit EBITDA|ANEW Medical, Inc. (KLTO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NeuroSense Therapeutics Ltd.|RVPH: Income before deduction of interest, taxes and amortization|Operating profit EBITDA MTVA|Operating profit EBITDA NeurAxis (NRXS)|Helius Medical Technologies, Inc. - Operating profit before deduction of amortization|Operating income before deduction of amortization Passage Bio, Inc. (PASG)|Neuphoria - Operating profit EBITDA|Income before deduction of interest, taxes and amortization NERV (Minerva)|ATHA: Operating profit EBITDA|Operating profit before amortization ADXN|Operating profit before deduction of amortization ALZN|Profit before interest, taxes and amortization Cyclerion Therapeutics CYCN|Profit before payment of interest, taxes and amortization Protagenic Therapeutics (PTIX)|Operating profit EBITDA Pasithea Therapeutics Corp (KTTA)|Cortigent, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Avenue Therapeutics ATXI|BCLI - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization CARA (Cara Therapeutics)|Chromocell Therapeutics Corporation (CHRO) - Profit before payment of interest, taxes and amortization|Eliem Therapeutics, Inc. - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization ITCI|Profit before interest, taxes and amortization longboardpharma.com LBPH|Profit before payment of interest, taxes and amortization Marinus (MRNS)|Company profit before taxes, interest and amortization NKGN|Operating profit EBITDA NRBO (NeuroBo)|Income before deduction of interest, taxes and amortization SAGE|SNPX: Operating profit before deduction of amortization|Profit before interest, taxes and amortization Trevena|VIGL: Operating profit EBITDA|WENA - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Cerevel
